Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3326-3334

  Engel, Juan C ^a   Ang, Kenny K H ^a   Chen, Steven ^a   Arkin, Michelle R ^a   McKerrow, James H ^a   Doyle, Patricia S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CYSTEINE PROTEINASE INHIBITOR; K 11777; NIFURTIMOX; POSACONAZOLE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CARDIOMYOPATHY; CELL NUCLEUS; CHAGAS DISEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GROWTH INHIBITION; HEART FAILURE; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; KINETOPLAST; NONHUMAN; PARASITE DEVELOPMENT; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; TRYPANOSOMA CRUZI;

ANIMALS; CATTLE; CELL LINE; CELL LINE, TUMOR; CHAGAS DISEASE; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MUSCLE, SKELETAL; PARASITIC SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 77955402138     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01777-09     Document Type: Article

References (65)

1. Abdulla, M. H., D. S. Ruelas, B. Wolff, J. Snedecor, K. C. Lim, F. Xu, A. R. Renslo, J. Williams, J. H. McKerrow, and C. R. Caffrey. 2009. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis. 3:478-480.
2. Añez, N., H. Carrasco, H. Parada, G. Crisante, A. Rojas, C. Fuenmayor, N. Gonzalez, G. Percoco, R. Borges, P. Guevara, and J. L. Ramirez. 1999. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg. 60:726-732.
3. Armstrong, J. W. 1999. A review of high-throughput screening approaches for drug discovery. Combinatorial Chem. Rev. http://www.combichemistry.com/ review.html.
4. Barcan, L., O. Luna, L. Clara, A. Sinagra, A. Valledor, A. M. De Rissio, A. Gadano, M. M. Garcia, E. de Santibañes, and A. Riarte. 2005. Transmission of T. cruzi infection via liver transplantation to a non-reactive recipient for Chagas' disease. Liver Transpl. 11:1112-1116. (Pubitemid 41341762)
5. Benaim, G., J. M. Sanders, Y. Garcia-Marchan, C. Colina, R. Lira, A. R. Caldera, G. Payares, J. M. Burgos, A. Leon-Rossell, J. L. Concepcion, A. G. Schijman, C. Sanoja, M. Levin, E. Oldfield, and J. A. Urbina. 2006. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem. 49:892-899.
6. Benson, T. J., J. H. McKie, J. Garforth, A. Borges, A. H. Fairlamb, and K. T. Douglas. 1992. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochem. J. 286:9-11.
7. Bettiol, E., M. Samanovic, A. S. Murkin, J. Raper, F. Buckner, and A. Rodriguez. 2009. Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl. Trop. Dis. 3:e384.
8. Beveridge, E., I. Caldwell, V. Latter, R. Neal, V. Udall, and M. Waldron. 1980. The activity against Trypanosoma cruzi and cutaneous leishmaniasis, and toxicity, of moxipraquine (349C59). Trans. R. Soc. Trop. Med. Hyg. 74:43-51.
9. Bocchi, E. A., and A. Fiorelli, for the First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. 2001. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann. Thorac. Surg. 71:1833-1838.
10. Botoni, F. A., P. A. Poole-Wilson, A. L. P. Ribeiro, D. O. Okonko, B. M. R. Oliveira, A. S. Pinto, M. M. Teixeira, A. L. Teixeira, Jr., A. M. Reis, J. B. D. Dantas, C. S. Ferreira, W. C. Tavares, Jr., and M. O. C. Rocha. 2007. A randomized trial of carvedilol aftermrenin-angiotensin system inhibition in chronic Chagas' cardiomyopathy. Am. Heart J. 153:544-548.
11. Buckner, F. S., C. L. Verlinde, A. C. La Flamme, and W. C. Van Voorhis. 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob. Agents Chemother. 40:2592-2597.
12. Campos, S. V., T. M. Strabelli, V. Amato Neto, P. Christiano, C. P. Silva, F. Fernando, A. Edimar, E. A. Bocchi, and N. A. G. Stolf. 2008. Risk factors for Chagas' disease reactivation after heart transplantation. J. Heart Lung Transplant. 27:597-602.
13. Castro, J. A., M. M. de Mecca, and L. C. Bartel. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25:471-479.
14. Chen, D., and Q. P. Dou. 2008. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin. Ther. Targets 12:739-748.
15. Chong, C.R., and D. J. Sullivan, Jr. 2007. New uses for old drugs. Nature 448:645-646.
16. Chung, M. C., V. R. C. Guido, T. F. Martinelli, M. F. Goncalves, M. C. Polli, K. C. A. Botelho, E. A. Varanda, C. Colli, T. M. Miranda, and E. I. Ferreira. 2003. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem. 11:4779-4783.
17. de Andrade, A. L., F. Zicker, R. M. de Oliveira, S. Almeida Silva, A. Luquetti, L. R. Travassos, I. C. Almeida, S. S. de Andrade, J. G. de Andrade, and C. M. Martelli. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413.
18. de Faria, J. B., and G. Alves. 1993. Transmission of Chagas' disease through cadaveric renal transplantation. Transplantation 56:1583-1584. (Pubitemid 24018840)
19. Derouin, F., and M. Santillana-Hayay. 2000. Anti-Toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob. Agents Chemother. 449:2575-2577.
20. Doyle, P. S., Y. M. Zhou, J. C. Engel, and J. H. McKerrow. 2007. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob. Agents Chemother. 51:3932-3939.
21. Doyle, P. S., M. Sajid, T. O'Brien, K. Dubois, J. C. Engel, Z. B. Mackey, and S. Reed. 2008. Drugs targeting parasite lysosomes. Curr. Pharm. Des. 14: 889-900.
22. Doyle, P. S., C. K. Chen, J. B. Johnston, S. D. Hopkins, S. S. F. Leung, M. P. Jacobson, J. C. Engel, J. H. McKerrow, and L. M. Podust. 2010. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob. Agents Chemother. 54:2480-2488.
23. Dvorak, J. A. 1984. The natural heterogeneity of Trypanosoma cruzi: biological and medical implications. J. Cell. Biochem. 24:357-371.
24. Elias, M. C., N. Vargas, L. Tomazi, A. Pedroso, B. Zingales, S. Schenkman, and M. R. Briones. 2005. Comparative analysis of genomic sequences suggests that Trypanosoma cruzi CL Brener contains two sets of non-intercalated repeats of satellite DNA that correspond to T. cruzi I and T. cruzi II types. Mol. Biochem. Parasitol. 140:221-227.
25. Engel, J. C., P. S. Doyle, and J. A. Dvorak. 1985. Trypanosoma cruzi: biological characterization of 19 clones from two chagasic patients. II. Quantitative analysis of the intracellular cell cycle. J. Protozool. 32:80-83.
26. Engel, J. C., P. S. Doyle, I. Hsieh, and J. H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188:725-734.
27. Evens, F., K. Niemegeers, and A. Packchanian. 1957. Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man. Am. J. Trop. Med. Hyg. 6:665-678.
28. Ferreira, A. W., and S. D. de Avila. 1995. Laboratory diagnosis of Chagas' heart disease. Sao Paulo Med. J. 13:767-771.
29. Ferreira, M. S., A. Nishioka Sde, M. T. Silvestre, A. S. Borges, F. R. Nunes-Araujo, and A. Rocha. 1997. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin. Infect. Dis. 25:1397-1400.
30. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
31. Gallerano, R. R., and R. R. Sosa. 2005. Interventional study in the natural evolution of Chagas' disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev. Fac. Cien. Med. Univ. Nac. Cordoba 57:135-162.
32. Garzon, S. A., A. M. Lorga, and J. C. Nicolau. 1995. Electrocardiography in Chagas' heart disease. Sao Paulo Med. J. 113:802-813.
33. Gould, M. K., X. L. Vu, T. Seebeck, and H. P. de Koning. 2008. Propidium iodide-based methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar Blue assay. Anal. Biochem. 382:87-93.
34. Grellier, P., V. Sinou, and J. Schrevel. 1995. Differential actions of antimicrotubular drugs on the development of Trypanosoma cruzi, the agent of Chagas' disease. Biol. Cell 84:92.
35. Gurtler, R. E., E. L. Segura, and J. E. Cohen. 2003. Congenital transmission of Trypanosoma cruzi infection in Argentina. Emerg. Infect. Dis. 9:29-32.
36. Gutierrez-Correa, J., A. H. Fairlamb, and A. O. Stoppani. 2001. Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic. Res. 34:363-378.
37. Hammond, D. J., B. Cover, and W. E. Gutteridge. 1984. A novel series of chemical structures active in vitro against the trypomastigote form of Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 78:91-95.
38. Jones-Brando, L., E. F. Torrey, and R. Yolken. 2003. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 62:237-244.
39. Kinnamon, K. E., B. T. Poon, W. L. Hanson, and V. B. Waits. 1998. Activity of anticancer compounds against Trypanosoma cruzi-infected mice. Am. J. Trop. Med. Hyg. 58:804-806.
40. Kirchhoff, L. V., P. Paredes, A. Lomeli-Guerrero, M. Paredes-Espinoza, C. S. Ron-Guerrero, M. Delgado-Mejia, and J. G. Pena-Munoz. 2006. Transfusion-associated Chagas' disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 46:298-304.
41. Lages-Silva, E., E. Crema, L. E. Ramirez, A. M. Macedo, S. D. Pena, and E. Chiari. 2001. Relationship between Trypanosoma cruzi and human chagasic megaesophagus: blood and tissue parasitism. Am. J. Trop. Med. Hyg. 65: 435-441.
42. Mackey, Z. B., A. M. Baca, J. P. Mallari, B. Apsel, A. Shelat, E. J. Hansell, P. K. Chiang, B. Wolff, K. R. Guy, J. Williams, and J. H. McKerrow. 2006. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des. 67:355-363.
43. McKerrow, J. H., P. S. Doyle, J. C. Engel, L. M. Podust, S. A. Robertson, R. Ferreira, T. Saxton, M. Arkin, I. D. Kerr, L. S. Brinen, and C. S. Craik. 2009. Two approaches to discovering and developing new drugs for Chagas' disease. Mem. Inst. Oswaldo Cruz 104:263-269.
44. Nakabayashi, H., K. Taketa, T. Yamane, M. Miyazaki, K. Miyano, and J. Sato. 1984. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Gann 75:151-158. (Pubitemid 14155204)
45. Olden, K. W. 2005. The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr. 10:891-896.
46. PAHO. 2006. Organización Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay, 2006. http://www.bvsops.org.uy/pdf/chagas19.
47. Pereira, K. S., F. L. Schmidt, A. M. Guaraldo, R. M. Franco, V. L. Dias, and L. A. Passos. 2009. Chagas' disease as a food borne illness. J. Food Prot. 72:441-446.
48. Pinto Dias, J. C. 2006. The treatment of Chagas' disease (South American trypanosomiasis). Ann. Intern. Med. 144:772-774.
49. Postan, M., J. J. Bailey, J. A. Dvorak, J. P. McDaniel, and E. W. Potala. 1987. Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection. Am. J. Trop. Med. Hyg. 37:541-549.
50. ProMED. 2005. Trypanosomiasis, foodborne-Brazil (Santa Catarina) ProMED-mail 24 Mar: 20050324.0847. http://www.promedmail.org.
51. Punukollum, G., R. M. Gowda, and I. A. Khan. 2004. Early twentieth century descriptions of the Chagas heart disease. Int. J. Cardiol. 95:347-349.
52. Rassi, A., Jr., S. G. Rassi, and A. Rassi. 2001. Sudden death in Chagas' disease. Arq. Bras. Cardiol. 76:75-96.
53. Ribeiro, A. L. P., A. M. dos Reis, M. V. L. Barros, M. R. de Sousa, A. L. L. Rocha, A. Arantes Perez, J. Braga Pereira, F. Santana Machado, and M. O. C. Rocha. 2002. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 360:461-462.
54. Samuel, J., M. Oliveira, R. R. Correa De Araujo, M. A. Navarro, and G. Mucillo. 1983. Cardiac thrombosis and thromboembolism in chronic Chagas' heart disease. Am. J. Cardiol. 52:147-151.
55. Sannella, A. R., A. Casini, C. Gabbiani, L. Messori, A. R. Bilia, F. F. Vincieri, G. Giancarlo Majori, and C. Severini. 2008. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 582:844-847.
56. Scanavacca, M., and E. Sosa. 1995. Electrophysiologic study in chronic Chagas' heart disease. Sao Paulo Med. J. 113:841-850.
57. Schmunis, G. A. 1999. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem. Inst. Oswaldo Cruz 94:93-101.
58. Seebeck, T., and P. Gehr. 1983. Trypanocidal action of neuroleptic phenothiazines in Trypanosoma brucei. Mol. Biochem. Parasitol. 9:197-208.
59. Torrance, C. J., V. Agrawal, B. Volgestein, and K. W. Kinzler. 2001. Use of human cancer cells for high throughput screening and discovery. Nat. Biotechnol. 19:940-945.
60. Triquell, M. F., C. Díaz-Luján, H. Freilij, P. Paglini, and R. E. Fretes. 2009. Placental infection by two subpopulations of Trypanosoma cruzi is conditioned by differential survival of the parasite in a deleterious placental medium and not by tissue reproduction. Trans. R. Soc. Trop. Med. Hyg. 103:1011-1018.
61. Villar, J. C., J. A. Marin-Neto, S. Ebrahim, and S. Yusuf. 2002. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst. Rev. 1:119-130.
62. Viotti, R., C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti. 2006. Long-term cardiac outcomes of treating chronic Chagas' disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144:724-734.
63. Weisman, J. L., A. P. Liou, A. A. Shelat, F. E. Cohen, R. K. Guy, and J. L. DeRisi. 2006. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67:409-416.
64. Wishart, D. S., C. Knox, A. C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and M. Hassanali. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36:D901-D906.
65. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.